Premium
Insights from the PLCO trial about prostate cancer screening
Author(s) -
Gulati Roman,
Albertsen Peter C.
Publication year - 2017
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.30472
Subject(s) - medicine , prostate cancer , prostate cancer screening , prostate , cancer screening , oncology , prostate specific antigen , cancer , screening test , gynecology , family medicine
Updated results from the US‐based Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial show durability of earlier findings demonstrating that up to 6 rounds of annual prostate‐specific antigen testing does not reduce prostate cancer mortality in comparison with historical screening practice. Although trials in Europe have estimated that certain screening programs can reduce prostate cancer mortality in comparison with no screening, the PLCO Cancer Screening Trial demonstrates that there are limits to the benefit that can be achieved. See also pages 592‐9.